41 results about "Ocular Infections" patented technology

The topical application of an azalide antibiotic such as azithromycin to the eye is useful in treating or preventing ocular infections. In one embodiment, the azalide antibiotic is supplied to the eye in a depot for sustained release. A more convenient dosing regimen can also be provided by the use of an appropriate depot. Furthermore, a composition containing a combination of medicaments is also provided.

Azalide antibiotics such as azithromycin are useful in the treatment and prevention of infections by bacteria and other parasites. Stabilized aqueous compositions containing azithromycin suitable for administration without reconstitution are provided for. Also provided for are aqueous formulations suitable for ocular administration in a employing a convenient dosing formulation suitable for administration in depot formats.

The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.

A method for treating ocular conditions such as bacterial keratitis, bacterial conjunctivitis, corneal ulcers and wounds, endophthalmitis, and blebitis in mammals, by using a native, synthetic, or recombinant CAP37, or effective peptide portions thereof including CAP37 peptides 20-44, 23-42, 102-122, and 120-146 and monocysteine derivatives of peptides 20-44 and 23-42. The CAP37, peptides, and peptide derivatives can also be used to store, clean, sterilize, or coat contact lenses, and may be used in media for storing mammalian corneal transplants.

The invention discloses an ophthalmic medicament and a preparation method thereof. The ophthalmic medicament comprises a phyllanthus emblica extract and water for injection. The ophthalmic medicamentcan provide a protective effect on viruses capable of being infected by eyes in a targeted manner; experimental research shows that the ophthalmic medicament has relatively efficient broad-spectrum antiviral activity, particularly has a remarkable treatment effect on new coronavirus and influenza virus, can effectively inhibit infection and propagation of the viruses, and has good prevention and control significance on propagation of diseases caused by virus infection on human bodies. The main effective components of the ophthalmic medicament are from natural plants, so that the ophthalmic medicament has the advantages of naturalness, safety, mild drug effect and the like, and the preparation method is simple, low in cost and very good in application prospect.

The present invention is directed to novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, and medical use of such compounds for the treatment and / or management of sepsis, septicemia, septic shock, ocular infection, ocular inflammation, ocular angiogenesis, rheumatoid arthritis (RA), atherosclerosis, inflammatory bowel diseases (IBD), asthma, chronic obstructive pulmonary disease, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, cancer and / or any disorder associated with inflammation, immunomodulation and microbial infection.

Compositions including a quinolone component, such as ofloxacin, having fungistatic activity in the compositions, present in an amount effective as an antibiotic when the composition is placed in a mammalian eye, a NSAID component present in an amount to reduce inflammation or pain when the composition is placed in the eye, and a carrier component in an amount effective to act as a carrier for the quinolone component and NSAID component are provided. Methods of using the present compositions, for example, to resolve microbial infections and / or to reduce inflammation and / or pain in a mammalian eye are included within the scope of the present invention. Methods for treating corneal injuries are also included. In addition, methods for treating ocular infections, for example, corneal infections, are included.

The present invention provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin / low molecular weight heparin derivative.

Polyhexamethylene guanidine eye drops relate to the technical field of eye drops, and comprise the following components by mass: 0.01%-0.1% of polyhexamethylene guanidine hydrochloride, 0.01% of a synergist, 0.1% of pharmaceutical grade hydroxy propyl methyl cellulose, 0.05% of PEG200 (polyethylene glycol), 0.05% of PEG6000, 0.05% of water soluble vitamin E, 0.01% of water-soluble mint, 0.1% of pure sodium chloride, and 99.53%-99.62% of pure water. Polyhexamethylene guanidine is used in the eye drops, and the polyhexamethylene guanidine eye drops are suitable for bacterial conjunctivitis, keratitis, keratohelcosis, dacryocystitis, postoperative infection and other external ocular infections, and is good in sterilization effect, mild in nature, and non-irritating.

In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms. The present invention provides, in various aspects, compounds and methods for the treatment of infections, such as biofilm infections or chronic biofilm infections. The chronic biofilm infection may occur in wounds, implanted devices, immunocompromised patients, people with cystic fibrosis, eye infections, etc.

Adenoviral infections and in particular ocular adenoviral infections, e.g. keratoconjunctivitis, can be treated or alleviated by the administration of a substance, interfering with the interaction between the virus and the sialic acid receptor, in a therapeutically effective amount.

Methods of treating a subject suffering from an ocular infection and / or ocular inflammation are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least two active agents in an ophthalmically acceptable vehicle that can provide a sustained release of the at least two active agents. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.

The present invention relates to a method for simultaneously detecting a plurality of pathogens from biologically-derived samples, and a kit for carrying out the method. Specifically, the present invention relates to a method for simultaneously detecting a plurality of pathogens that cause infectious uveitis, one of eye infections from samples such as anterior chamber fluid or vitreous by polymerase chain reaction (PCR), and a kit for carrying out the method.

Methods and pharmaceutical compositions (or delivering a therapeutic agent, treating a neovascularization disorder, and treating an ocular infection include make use of a compound that includes an clastin-likc polypeptide (ELP) coupled to a therapeutic agent, wherein the ELP comprises at least one repeat of the amino acid sequence VPGXG (SEQ ID NO: 1), and where the composition is suitable for ocular administration.

Instillation of a 1.5% (w / v) levofloxacin ophthalmic solution three times a day, which is the dosage or dose regimen of the present invention, has features to cure bacterial conjunctivitis in a shorter time than instillation of a 0.5% (w / v) ophthalmic solution three times a day, which is the conventional dosage or dose regimen, and not to increase the rate of occurrence of side effects. Curing the ocular infection in a short time leads to shortening of the duration of exposure of the ocular-infection-causing bacterium to levofloxacin. Therefore, the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention is eventually expected to suppress emergence of the resistant bacterium resulting from the long-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen. In addition, it is confirmed that the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention directly inhibits the ocular-infection-causing bacterium such as Staphylococcus aureus from becoming resistant to levofloxacin, which results from the short-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen.

Neurokinin 1 receptor (NK1R) agonist mediated protection of the eye is described. The protection can reduce dry eye and ocular infections, particularly in individuals with reduced NK1R activity.

The invention belongs to the technical field of nucleic acid detection, and particularly relates to a real-time fluorescent multiple PCR (Polymerase Chain Reaction) rapid detection kit for common pathogens leading to ocular infection. According to the rapid detection kit, the problem of cross linkage among different primers / probes is avoided, each set of primer / probe is prevented from generating cross homology on other target / non-target nucleic acid sequences, various common pathogens leading to ocular infection can be detected simultaneously in one reaction, the detection time required is short, the accuracy is high, and a powerful detection tool is provided for the clinic and detection laboratories.

The invention provides compositions comprising carboline compounds for treating infections such as viral conjunctivitis. The invention also provides methods for treating of other infections, including ocular infections. More particularly, the present invention relates to compositions comprising carboline compounds for the treatment of ocular infections such as viral conjunctivitis, particularly those caused by adenovirus

The subject invention provides materials and methods for reducing ocular infections in subjects. The materials and methods utilize chlorhexidine, which has been found to be unexpectedly non-toxic to humans and other animals in low concentrations. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought possible.

The invention provides a corynebacterium and an application of the corynebacterium in ocular surface fungal infection resistance, the corynebacterium is a corynebacterium macginleyi C.mac2 strain, the corynebacterium is preserved in the China General Microbiological Culture Collection Center on November 16, 2021, and the preservation number is CGMCC No.23924. The invention further provides a preparation method of the corynebacterium and an application of the corynebacterium in ocular surface fungal infection resistance. The invention further provides a new application of the corynebacterium, namely application of the corynebacterium in preparation of products for treating ocular surface diseases of different individuals. The invention further provides a product capable of being colonized on the ocular surface. The product is used for preventing and treating ocular surface diseases caused by fungal infection. Wherein the culture medium contains the corynebacterium and the product thereof. The corynebacterium provided by the invention does not induce eye infection under normal conditions, and when the corynebacterium is colonized on the ocular surface, the immunity of the ocular surface can be enhanced, and the cornea can be protected from fungal infection.

The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans and animals including mammals and birds. More particularly, it relates to subunit vaccines that are effective against pathogens causing infections thereof for use in humans and animals including mammals and birds. The present invention specifically provides a novel vaccine formulation suitable for ocular immunization comprising a subunit vaccine antigen in an amount to provoke a protective immune response and at least two adjuvants of which one is corpuscular. It further provides a method for inducing a local and systemic immune response and methods for preventing recurrence of ocular infections and / or modulates the occurrence and / or severity of sequels.

An ophthalmic composition useful for the treatment of bacterial eye infections is provided. The ophthalmic composition includes the suspension of particles of active anti-bacterial agent in a gelled matrix.

A microbial infection in an eye of a subject is treated or prevented by topically administering to the eye an effective amount of a macromolecule or a pharmaceutically acceptable salt thereof that includes a dendrimer of 1 to 8 generations with one or more sulfonic acid- or sulfonate-containing moieties attached to one or more surface groups of the outermost generation of the dendrimer. Compositions containing the macromolecule or salt are useful in these methods.

Adenoviral infections and in particular ocular adenoviral infections, e.g. kerato-conjunctivitis, can be treated or alleviated by the administration of a substance, interfering with the interaction between the virus and the sialic acid receptor, in a therapeutically effective amount.

The invention provides a compound oxytetracycline oculentum for pets, the compound oxytetracycline oculentum comprises, by mass, 0.5-5% of an active component and 95-99.5% of an oculentum matrix, the active component comprises oxytetracycline hydrochloride and polymyxin B sulfate, and the oculentum matrix comprises albolene and liquid paraffin. The raw materials and the auxiliary materials are medicinal, the quality is easy to control, and the preparation is convenient; the active ingredients are anti-infection western medicine ingredients which are clear and are safer than some complex traditional Chinese medicine ingredients; and the compound oxytetracycline oculentum for pets has an obvious effect on treating eye infection of pets.